Asgard Therapeutics

Asgard Therapeutics is a biotech company developing gene therapy approaches for cancer immunotherapy based on direct cell reprogramming. Its lead program, AT-108, is an off-the-shelf gene therapy designed to induce immune responses by mimicking the properties of professional antigen-presenting cells. The technology aims to overcome manufacturing hurdles associated with conventional cell-based therapies by providing a personalized yet standardized treatment option.